Table A2.
Histopathologic Evaluation of Liposarcoma
| Sarcoma Subtype | Biopsy Site | Biopsy Composition | Biopsy Collection Time | Ratio (cell to stroma) | Necrosis (%) | Ki67-Positive Tumor Cells (%) | Overall Treatment Response |
|---|---|---|---|---|---|---|---|
| DD liposarcoma | Left abdominal wall | 85% nonlipogenic component; 10% lipogenic component | Pretreatment | 90:10 | 5 | 35 | Marked reduction in cellularity, increased necrosis, and strong stromal response |
| During treatment | 10:90 | 45 | 5 | ||||
| DD liposarcoma | Lower left quadrant pelvic mass | 100% nonlipogenic component; 0% lipogenic component | Pretreatment | 85:15 | 0 | 55 | Moderate reduction in cellularity, minimal necrosis, and increased stromal response |
| During treatment | 75:25 | 5 | 45 | ||||
| DD liposarcoma | Left mesenteric mass | 100% nonlipogenic component; 0% lipogenic component | Pretreatment | 95:5 | 35 | 70 | Moderate reduction in cellularity, no necrosis, and increased stromal response |
| During treatment | 80:20 | 0 | 60 | ||||
| DD liposarcoma | Pelvic mass | 100% nonlipogenic component; 0% lipogenic component | Pretreatment | 80:20 | 0 | 30 | Moderate reduction in cellularity, no necrosis, and increased stromal response |
| During treatment | 60:40 | 0 | 25 | ||||
| DD liposarcoma | Pelvic mass | 5% nonlipogenic component; 95% lipogenic component | Pretreatment | ND | 0 | 65 | No response |
| During treatment | 0 | 65 |
Abbreviations: DD, dedifferentiated; ND, not determined.